8-K: Propanc Biopharma Secures $30,375 in Funding Through Convertible Promissory Note

Propanc Biopharma has entered into a securities purchase agreement, securing $30,375 in funding through a convertible promissory note with a principal amount of $33,750.

Summary

• Propanc Biopharma, Inc. has issued a convertible promissory note to 104 LLC for a purchase price of $30,375, with a principal amount of $33,750.
• The note includes an original issue discount of $3,375 and carries a 10% annual interest rate, with the first twelve months of interest guaranteed.
• The maturity date of the note is twelve months from the issue date, June 20, 2024, making it due on June 20, 2025.
• The note can be converted into common stock at 65% of the lowest daily closing trade price in the previous ten trading days, representing a 35% discount.
• The conversion is subject to a 4.99% beneficial ownership limitation.
• The company is required to reserve a minimum of 237,000,000 shares of common stock for potential conversion, or five times the number of shares issuable upon full conversion, whichever is greater.
• The company has the option to prepay the note within the first six months with a premium ranging from 110% to 125% of the principal amount, plus accrued interest and a $750 administrative fee.
• If the company receives cash proceeds from any source, the holder has the right to require the company to immediately apply up to 100% of such proceeds to repay the note.
• The note has priority over all unsecured indebtedness of the company.
• The company is restricted from incurring additional senior or pari passu unsecured debt, paying dividends, repurchasing stock, or selling significant assets without the holder's consent.

Sentiment

Score: 6

Explanation: The document indicates a necessary but potentially dilutive financing event. While the company secures funding, the terms of the note and the restrictions imposed suggest a moderate level of risk and uncertainty.

Positives

• The company has secured immediate funding of $30,375.
• The note provides a guaranteed interest payment for the first year.
• The conversion feature offers potential upside for the investor through a 35% discount on the stock price.
• The prepayment option allows the company to manage its debt obligations.
• The note's priority over unsecured debt provides security for the investor.
• The ability to demand repayment from cash proceeds provides a mechanism for the investor to recoup their investment.

Negatives

• The company is subject to restrictions on incurring additional debt, paying dividends, and repurchasing stock.
• The conversion of the note could dilute existing shareholders.
• The company is obligated to maintain a significant reserve of shares for potential conversion.
• The company is subject to a 16% default interest rate if payments are not made on time.
• The company is restricted from selling significant assets without the holder's consent.
• The company is restricted from entering into certain transactions without the holder's consent.

Risks

• Failure to meet payment obligations could trigger a default and a 16% default interest rate.
• The conversion of the note could significantly dilute existing shareholders.
• The company's ability to operate is restricted by the covenants in the note.
• The company's share price could be negatively impacted by the issuance of new shares upon conversion.
• The company may face challenges in maintaining the required share reserve for conversion.
• The company may be forced to use cash proceeds to repay the note, limiting its operational flexibility.

Future Outlook

The company intends to use the net proceeds from the note for general working capital purposes. The note's conversion feature and the company's obligations to maintain a share reserve suggest a potential future increase in the number of outstanding shares.

Management Comments

• The company intends to use the net proceeds therefrom for general working capital purposes.

Industry Context

This type of financing, a convertible promissory note, is common for smaller companies seeking capital. The terms, including the discount on conversion and the interest rate, are typical for such agreements, reflecting the risk associated with investing in smaller, potentially volatile companies.

Comparison to Industry Standards

• The 35% discount on conversion is relatively standard for convertible notes in the micro-cap space, reflecting the higher risk profile of these investments.
• The 10% interest rate is within the typical range for such notes, though it can vary based on the perceived risk of the company.
• The 4.99% beneficial ownership limitation is a common clause to prevent the investor from gaining too much control of the company.
• The prepayment options are also standard, allowing the company to manage its debt while providing a premium to the investor.
• The covenants restricting the company's activities are typical for these types of financing agreements, designed to protect the investor's interests.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may benefit from the company's improved working capital.
• Creditors may be impacted by the note's priority over unsecured debt.
• Customers and suppliers may see no immediate impact, but the company's financial stability could be improved.

Next Steps

• The company will use the funds for working capital.
• The investor may convert the note into common stock at any time after the issue date.
• The company may prepay the note within the first six months.
• The company must maintain a reserve of shares for potential conversion.
• The company must comply with the covenants and restrictions outlined in the note.

Key Dates

Keywords

convertible promissory note, funding, common stock, conversion, debt, securities purchase agreement, dilution, prepayment, interest rate, default